Why Journalists Won’t Investigate the Trans Medical Industry -Gerald Posner (#15)
Gerald Posner — Pulitzer finalist, former lawyer, and veteran pharmaceutical investigator — joins Stella O'Malley and the Beyond Gender team to expose the financial machinery driving the trans medical industry. Drawing direct parallels with the opioid crisis, Posner asks the questions Irish media has been equally reluctant to raise: who profits when children become lifelong patients, and why are the warning signs being ignored again? For a country with its own history of pharmaceutical failure and institutional silence, this episode lands with particular urgency.
Gerald Posner is not a culture-war commentator. He is a Pulitzer Prize finalist, a former lawyer, and a journalist who spent years investigating the pharmaceutical industry's most damaging chapters. When someone with that track record argues that gender medicine is following a familiar and dangerous script, it deserves serious attention — in Ireland as much as anywhere else. At the heart of this conversation is the question of money. Posner traces what he describes as the pharma playbook: the same pattern of off-label prescribing, the same suppression of inconvenient data, and the same institutional capture that drove the opioid crisis now appearing in the market for puberty blockers and cross-sex hormones. The parallel is not rhetorical flourish. Opioids were also promoted as safe, necessary, and compassionate before the damage became undeniable. Ireland has its own painful history with pharmaceutical scandals — from Thalidomide to the cervical check controversy — and Posner's warnings carry particular weight for a country that has seen how quickly professional consensus can collapse. Posner also discusses leaked WPATH emails, which appear to show political considerations shaping what were presented as purely clinical guidelines. For Irish practitioners and policymakers who have relied on WPATH standards to inform HSE protocols, this raises uncomfortable questions about the foundations on which current practice rests. If the guidelines themselves were influenced by ideology rather than evidence, then the institutions that adopted them uncritically share in the responsibility for outcomes. One of the episode's most striking threads is its examination of media failure. Posner describes how editors at major publications have declined to pursue stories that credible reporters brought to them — not because the journalism was weak, but because the subject matter was politically sensitive. Irish audiences will recognise the dynamic. With a handful of exceptions, mainstream Irish media has shown little appetite for investigative scrutiny of gender medicine, leaving parents, detransitioners, and clinicians with legitimate concerns effectively without a platform. A specific focus of the conversation is an FDA regulatory loophole that allows drugs to be prescribed for uses never properly studied or approved. In Ireland, prescribing operates under different frameworks, but the underlying problem — that children are receiving experimental interventions without the safeguards that would normally apply to a clinical trial — is the same. Stella O'Malley, who has spent years working with young people experiencing gender distress, brings her clinical perspective to bear on these findings, pressing Posner on what genuine accountability might look like. This episode is not an argument against compassion for gender-distressed young people. It is an argument that compassion without rigour has consequences, and that the institutions meant to prevent those consequences — regulatory bodies, professional associations, and the press — have in this case fallen short. For Irish listeners wondering why so little of this scrutiny has appeared in their own news feeds, Gerald Posner offers a sobering and detailed answer.
